Other clinical data concerning melanoma patients have provided evidence that the combination of radiotherapy with a dual-checkpoint blockade, including anti-CTLA-4 and anti-PD-L1 antibodies, could promote an immune response through distinct mechanisms. The gene discussed is CD274; the disease is melanoma.